The Effect of a Multi-Component Nutraceutical Supplement on Dyslipidemia, Glycemic Control, and Blood Pressure: A Preliminary Prospective Observational Pilot Study

Abstract

Early metabolic abnormalities, including borderline dyslipidemia, mildly elevated blood pressure, and impaired glycemic control, are associated with increased cardiometabolic risk. This study aimed to explore whether a multi-component nutraceutical formulation, CARDIO360, was associated with favorable changes in lipid and glycemic parameters in adults with early metabolic dysfunction. A prospective, non-randomized, open-label observational study was conducted in 50 adults aged 35–78 years with borderline dyslipidemia, mildly elevated blood pressure, and/or HbA1c levels between 5.8% and 6.9%. A total of 30 participants received CARDIO360 for 120 days, while 20 participants served as controls and received standard lifestyle advice without nutraceutical supplementation. Clinical and biochemical parameters were assessed at baseline and after 120 days. Between-group differences in changes from baseline were analyzed. Compared with controls, CARDIO360 was associated with significantly greater reductions in total cholesterol, LDL cholesterol, and HbA1c. No significant between-group effect was observed for systolic blood pressure, diastolic blood pressure, HDL cholesterol, or heart rate. No serious adverse events were reported during the follow-up period. The observed improvements in lipid profile and glycemic control suggest a preliminary metabolic signal of CARDIO360 in individuals with early cardiometabolic abnormalities. However, the non-randomized, open-label design, small sample size, lack of a placebo control, and lack of structured monitoring of diet and physical activity limit causal interpretation. CARDIO360 supplementation was associated with exploratory improvements in lipid and glycemic parameters over 120 days. These findings should be considered hypothesisgenerating and require confirmation in larger randomized, placebo-controlled trials with standardized lifestyle monitoring and longer follow-up.